ProclaRx to Present on New Bacterial Biofilm Therapies at Biotech Showcase January 11- 13, 2016 in San Francisco

Jan 05, 2016, 08:35 ET from ProclaRx

COLUMBUS, Ohio, Jan. 5, 2016 /PRNewswire/ -- ProclaRx LLC, formerly known as Lattice Biotech LLC, has been selected to speak at the 8th Annual Biotech Showcase on January 11 and the Medtech Showcase, January 12, 2016, regarding their breakthrough medical discovery for treatment of patients with serious bacterial infections.

The Ohio based biotechnology company has developed a technology to break down and destroy biofilms, a physical barrier which protects bacteria and prevents antibiotics and the body's immune system from eradicating chronic infections.

Infections with biofilms are associated with indications as those found in advanced wound care, chronic draining ear infections, and CVID sinusitis. They are highly resistant to antibiotics and have a significant ability to evade normal defenses against bacteria. Recurrent infections and antibiotic resistance is a major clinical and public health problem, with bacterial biofilms implicated in more than 80% of infections.

"The ProclaRx biofilm technology addresses an important unmet medical need that will enable effective treatment for numerous chronic bacterial infections," states Dr. Tom Zupancic, Chief Scientific Officer and co-founder. "Our patented platform technology disrupts the biofilm fortress and enables both the body's immune system and antibiotics to better attack the disease." 

Founded in 2014, ProclaRx has exclusive worldwide rights to develop and commercialize

anti-infective technology from the University of Southern California, Ohio State University and Nationwide Children's Hospital. With $5.5 million invested to-date, they are seeking additional financing and strategic partners. The Biotech Showcase is one of the healthcare industry's largest annual healthcare investor conferences.   

About ProclaRx
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, secretory otitis media and CVID sinusitis. Visit www.proclarx.com or call 949-302-2165 or e-mail info@proclarx.com.

Contact:  Dr. Joseph D. Kittle, Jr.
CEO, ProclaRx
949-302-2165  

SOURCE ProclaRx



RELATED LINKS

http://www.proclarx.com